Following a surge in circumstances of coronavirus illness 2019 (COVID-19) in June 2020, India grew to become the third-worst affected nation worldwide. This examine goals to analyse the underlying epidemiological scenario in India and clarify attainable impacts of policy and technological modifications. Secondary knowledge have been utilized, together with not too long ago revealed literature from authorities sources, the COVID-19 India web site and native media stories. These knowledge have been analysed, with a concentrate on the affect of policy and technological interventions.
The unfold of COVID-19 in India was initially characterised by fewer circumstances and decrease case fatality charges in contrast with numbers in many developed international locations, primarily on account of a stringent lockdown and a demographic dividend. However, financial constraints compelled a staggered lockdown exit technique, ensuing in a spike in COVID-19 circumstances. This issue, coupled with low spending on well being as a share of gross home product (GDP), created mayhem as a result of of insufficient numbers of hospital beds and ventilators and a scarcity of medical personnel, particularly in the public well being sector. Nevertheless, technological advances, supported by a robust analysis base, helped include the injury ensuing from the pandemic.
Following nationwide lockdown, the Indian economic system was hit exhausting by unemployment and a steep decline in development. The early implementation of lockdown initially decreased the doubling fee of circumstances and allowed time to upscale important medical infrastructure. Measures resembling asymptomatic testing, public-private partnerships, and technological advances will probably be important till a vaccine will be developed and deployed in India. Low spending on well being as a share of gross home product (GDP) meant there was a scarcity of hospital beds and ventilators and a scarcity of medical personnel, particularly in the public well being sector.
The unfold of COVID-19 in India was initially characterised by decrease case numbers and fewer deaths in contrast with numbers in many developed international locations. This was primarily on account of a stringent lockdown and demographic elements. However, financial constraints compelled a staggered lockdown exit technique, ensuing in a spike in COVID-19 circumstances in June 2020. Subsequently, India grew to become the third-worst affected nation worldwide. Nevertheless, technological advances, supported by a robust analysis base, helped include the well being and financial injury ensuing from the pandemic. In the future, measures resembling asymptomatic testing, public-private partnerships, and technological advances will probably be important till a vaccine towards COVID-19 will be developed and rolled-out in India.
Community Perspectives on Communicating About Precision Medicine in an Alaska Native Tribal Health Care System
Precision drugs seeks to higher tailor medical care to the wants of particular person sufferers, however there are challenges concerned in speaking to sufferers, well being care suppliers, and well being system leaders about this novel and advanced strategy to analysis and scientific care. These challenges could also be exacerbated for Alaska Native and American Indian (ANAI) individuals, whose experiences of unethical analysis practices have left some ANAI communities hesitant to have interaction in analysis that includes in depth data-sharing and diminished management over the phrases of knowledge administration and who might have distinct, culturally-informed communication wants and preferences.
There is want for communication analysis to assist Tribal well being organizations and ANAI individuals as they think about implementation of and participation in precision drugs. To handle that want, this examine characterizes the informational wants and communication preferences of sufferers, suppliers, and leaders at an Alaska Native Tribal well being group. We carried out 46 particular person, semi-structured interviews to discover views on precision drugs and associated communication wants amongst sufferers, suppliers, and leaders of a Tribal well being group. Analysis concerned team-based coding to determine a priori and emergent themes, adopted by identification and recoding of content material related to precision drugs informational wants and communication preferences.
Patients, suppliers, and leaders have been described as each sources and recipients of details about precision drugs. Information deemed important for making choices about whether or not to take part in or implement a precision drugs program included details about the scientific and analysis functions of precision drugs, advantages and dangers, well being system prices and impacts, and knowledge administration practices. Preferred communication channels included digital and non-digital informational supplies, in addition to in-person studying alternatives for people and teams. Participants additionally describe contextual elements and limitations that influenced the acceptability and effectiveness of approaches to well being communication.
Protocol for a Coordinated Approach for Building Capacity of Mental Health Researchers in India
India’s National Mental Health Programme (NMHP) was initiated in 1982. In 2016, the Indian Council of Medical Research (ICMR) organized a Brainstorming Meeting on Prioritization of Mental Health Research. Recognizing the want for enhancing psychological healthcare by constructing a cadre of psychological well being analysisers primarily based on focus areas of the NMHP, the ICMR organized a analysis coaching cum capability constructing workshop in collaboration with the Cross-Fertilized Research Training Programme (funded by Fogarty International Centre, NIH, USA) in 2016.
The workshop efficiently ready and reviewed 12 single and multicenter analysis proposals in precedence areas of psychological well being analysis, which have been awarded by the ICMR to middle- and junior-level analysis college and NGO. A National Coordination Unit (NCU) was set as much as mentor investigators and to coordinate, prepare, and monitor the progress of their initiatives. Investigators have been paired with senior mentors and additionally participated in 4 capability constructing workshops specializing in proposal-writing, analysis, and course of monitoring.
 Mouse Serum albumin antibody |
|
MBS535059-2mL |
MyBiosource |
2mL |
EUR 590 |
Mouse Serum albumin antibody |
|
MBS535059-5x2mL |
MyBiosource |
5x2mL |
EUR 2500 |
 Mouse serum albumin antibody ELISA kit |
|
E01A25349 |
BlueGene |
96T |
EUR 700 |
|
Description: ELISA |
Mouse serum albumin antibody ELISA kit |
|
E03S0304-192T |
BlueGene |
192 tests |
EUR 1524 |
|
|
|
Description: A competitive ELISA for quantitative measurement of Mouse serum albumin antibody in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species. |
Mouse serum albumin antibody ELISA kit |
|
E03S0304-48 |
BlueGene |
1 plate of 48 wells |
EUR 624 |
|
|
|
Description: A competitive ELISA for quantitative measurement of Mouse serum albumin antibody in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species. |
Mouse serum albumin antibody ELISA kit |
|
E03S0304-48wellsplate |
BlueGene |
48 wells plate |
EUR 280 |
Mouse serum albumin antibody ELISA kit |
|
E03S0304-96 |
BlueGene |
1 plate of 96 wells |
EUR 822 |
|
|
|
Description: A competitive ELISA for quantitative measurement of Mouse serum albumin antibody in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species. |
Mouse serum albumin antibody ELISA kit |
|
E03S0304-96wellsplate |
BlueGene |
96 wells plate |
EUR 405 |
 Mouse Serum Albumin Polyclonal Antibody |
|
A57545 |
EpiGentek |
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
|
- 100 µg
- 20 ul
- 50 ul
- 100 ul
|
 Mouse serum albumin Polyclonal Antibody |
|
MBS9237555-01mL |
MyBiosource |
0.1mL |
EUR 415 |
Mouse serum albumin Polyclonal Antibody |
|
MBS9237555-5x01mL |
MyBiosource |
5x0.1mL |
EUR 1841 |
 Mouse anti-Bovine Serum Albumin Antibody |
|
DL95468A-100ul |
DL Develop |
100 ul |
EUR 360 |
|
|
Mouse anti-Bovine Serum Albumin Antibody |
|
DL95468A-50ul |
DL Develop |
50 ul |
EUR 252 |
|
|
Mouse anti-Bovine Serum Albumin Antibody |
|
YLD8407-100ul |
Shanghai YL Biotech |
100 ul |
EUR 320 |
|
|
|
Description: Mouse monoclonal antibody to Bovine Serum Albumin |
Mouse anti-Bovine Serum Albumin Antibody |
|
YLD8407-50ul |
Shanghai YL Biotech |
50 ul |
EUR 200 |
|
|
|
Description: Mouse monoclonal antibody to Bovine Serum Albumin |
 Mouse anti-Human Serum Albumin Antibody |
|
DL95806A-100ul |
DL Develop |
100 ul |
EUR 310 |
|
|
|
Description: Serum albumin |
Mouse anti-Human Serum Albumin Antibody |
|
DL95806A-50ul |
DL Develop |
50 ul |
EUR 217 |
|
|
|
Description: Serum albumin |
Mouse anti-Human Serum Albumin Antibody |
|
YLD8508-100ul |
Shanghai YL Biotech |
100 ul |
EUR 320 |
|
Description: Mouse monoclonal antibody to Human Serum Albumin |
Mouse anti-Human Serum Albumin Antibody |
|
YLD8508-50ul |
Shanghai YL Biotech |
50 ul |
EUR 200 |
|
Description: Mouse monoclonal antibody to Human Serum Albumin |
 Mouse monoclonal Human Serum Albumin antibody |
|
MBS5306407-1mg |
MyBiosource |
1mg |
EUR 415 |
Mouse monoclonal Human Serum Albumin antibody |
|
MBS5306407-5x1mg |
MyBiosource |
5x1mg |
EUR 1710 |
 Serum Albumin Antibody |
|
48145 |
SAB |
100ul |
EUR 429 |
Serum Albumin Antibody |
|
48145-100ul |
SAB |
100ul |
EUR 399.6 |
Serum Albumin Antibody |
|
48145-50ul |
SAB |
50ul |
EUR 286.8 |
Serum Albumin Antibody |
|
MBS9435016-005mL |
MyBiosource |
0.05mL |
EUR 325 |
Serum Albumin Antibody |
|
MBS9435016-01mL |
MyBiosource |
0.1mL |
EUR 445 |
Serum Albumin Antibody |
|
MBS9435016-5x01mL |
MyBiosource |
5x0.1mL |
EUR 1860 |
 Mouse Serum Albumin |
|
CSB-NP000801m |
Cusabio |
10mg |
Ask for price |
 Mouse Serum albumin |
|
MBS571996-10mg |
MyBiosource |
10mg |
EUR 395 |
Mouse Serum albumin |
|
MBS571996-5x10mg |
MyBiosource |
5x10mg |
EUR 1625 |
Mouse Serum Albumin |
|
MBS7615609-INQUIRE |
MyBiosource |
INQUIRE |
Ask for price |
Mouse Serum Albumin |
|
MBS717450-100mg |
MyBiosource |
100mg |
EUR 635 |
Mouse Serum Albumin |
|
MBS717450-10mg |
MyBiosource |
10mg |
EUR 180 |
Mouse Serum Albumin |
|
MBS717450-1g |
MyBiosource |
1g |
EUR 2930 |
Mouse Serum Albumin |
|
MBS717450-1mg |
MyBiosource |
1mg |
EUR 135 |
Mouse Serum Albumin |
|
MBS717450-5x1g |
MyBiosource |
5x1g |
EUR 13130 |
 Human Serum Albumin Mouse Monoclonal Antibody |
|
E10G20494 |
EnoGene |
100 μl |
EUR 275 |
|
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody |
Human Serum Albumin Mouse Monoclonal Antibody |
|
E10G20712 |
EnoGene |
100 μl |
EUR 275 |
|
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody |
Human Serum Albumin Mouse Monoclonal Antibody |
|
E10G20713 |
EnoGene |
100 μl |
EUR 275 |
|
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody |
 Bovine Serum Albumin Mouse Monoclonal Antibody |
|
EM1190-100ul |
ELK Biotech |
100ul |
EUR 124 |
|
|
|
Description: WB |
Bovine Serum Albumin Mouse Monoclonal Antibody |
|
EM1190-50ul |
ELK Biotech |
50ul |
EUR 74 |
|
|
|
Description: WB |
Bovine Serum Albumin Mouse Monoclonal Antibody |
|
E12-420 |
EnoGene |
100μg/100μl |
EUR 225 |
|
Description: Available in various conjugation types. |
Bovine Serum Albumin Mouse Monoclonal Antibody |
|
E10G20442 |
EnoGene |
100 μl |
EUR 275 |
|
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody |
Bovine Serum Albumin Mouse Monoclonal Antibody |
|
MBS8510446-01mg |
MyBiosource |
0.1mg |
EUR 305 |
Bovine Serum Albumin Mouse Monoclonal Antibody |
|
MBS8510446-01mLAF405L |
MyBiosource |
0.1mL(AF405L) |
EUR 465 |
Bovine Serum Albumin Mouse Monoclonal Antibody |
|
MBS8510446-01mLAF405S |
MyBiosource |
0.1mL(AF405S) |
EUR 465 |
Bovine Serum Albumin Mouse Monoclonal Antibody |
|
MBS8510446-01mLAF610 |
MyBiosource |
0.1mL(AF610) |
EUR 465 |
Bovine Serum Albumin Mouse Monoclonal Antibody |
|
MBS8510446-01mLAF635 |
MyBiosource |
0.1mL(AF635) |
EUR 465 |
 antibody (IgG) ELISA Kit) Mouse serum albumin (BSA) antibody (IgG) ELISA Kit |
|
MBS7209385-10x96StripWells |
MyBiosource |
10x96-Strip-Wells |
EUR 5685 |
Mouse serum albumin (BSA) antibody (IgG) ELISA Kit |
|
MBS7209385-48StripWells |
MyBiosource |
48-Strip-Wells |
EUR 485 |
Mouse serum albumin (BSA) antibody (IgG) ELISA Kit |
|
MBS7209385-5x96StripWells |
MyBiosource |
5x96-Strip-Wells |
EUR 3020 |
Mouse serum albumin (BSA) antibody (IgG) ELISA Kit |
|
MBS7209385-96StripWells |
MyBiosource |
96-Strip-Wells |
EUR 690 |
) Serum Albumin Antibody (HRP) |
|
abx107862-100g |
Abbexa |
100 µg |
EUR 362.5 |
Serum Albumin Antibody (HRP) |
|
20-abx107862 |
Abbexa |
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
|
- 20 ug
- 50 ug
- 100 ug
- 200 ug
- 1 mg
|
|
|
Serum Albumin Antibody (HRP) |
|
abx107862-20g |
Abbexa |
20 µg |
EUR 162.5 |
Serum Albumin Antibody (HRP) |
|
abx107862-50g |
Abbexa |
50 µg |
EUR 250 |
 Rat Serum Albumin antibody |
|
MBS534979-20mg |
MyBiosource |
20mg |
EUR 650 |
Rat Serum Albumin antibody |
|
MBS534979-5x20mg |
MyBiosource |
5x20mg |
EUR 2775 |
) Mouse Serum albumin (Alb) |
|
1-CSB-BP001561MO |
Cusabio |
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
|
- 10ug
- 50ug
- 100ug
- 200ug
- 500ug
- 1MG
|
|
|
|
Description: Recombinant Mouse Serum albumin(Alb) expressed in Baculovirus |
Mouse Serum albumin (Alb) |
|
1-CSB-YP001561MO |
Cusabio |
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
|
- 10ug
- 50ug
- 100ug
- 200ug
- 500ug
- 1MG
|
|
|
|
Description: Recombinant Mouse Serum albumin(Alb) expressed in Yeast |
) Serum Albumin Antibody (FITC) |
|
abx106448-100g |
Abbexa |
100 µg |
EUR 362.5 |
Serum Albumin Antibody (FITC) |
|
20-abx106448 |
Abbexa |
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
|
- 20 ug
- 50 ug
- 100 ug
- 200 ug
- 1 mg
|
|
|
Serum Albumin Antibody (FITC) |
|
abx106448-20g |
Abbexa |
20 µg |
EUR 162.5 |
Serum Albumin Antibody (FITC) |
|
abx106448-50g |
Abbexa |
50 µg |
EUR 250 |
 Human Serum Albumin Antibody |
|
48062-100ul |
SAB |
100ul |
EUR 399.6 |
Human Serum Albumin Antibody |
|
48062-50ul |
SAB |
50ul |
EUR 286.8 |
 Human Serum Albumin Antibody |
|
6965-100 |
Biovision |
each |
EUR 405.6 |
Human Serum Albumin Antibody |
|
6965-30T |
Biovision |
each |
EUR 175.2 |
Human Serum Albumin Antibody |
|
GWB-E0B422 |
GenWay Biotech |
0.5 mg |
Ask for price |
Human Serum Albumin Antibody |
|
GWB-A687ED |
GenWay Biotech |
0.1 mg |
Ask for price |
Human Serum Albumin Antibody |
|
GWB-83170C |
GenWay Biotech |
1 ml |
Ask for price |
Human Serum Albumin Antibody |
|
E8M0809-4a |
EnoGene |
100μl |
EUR 225 |
|
Description: Available in various conjugation types. |
 Human Serum Albumin antibody |
|
MBS531801-1mg |
MyBiosource |
1mg |
EUR 280 |
Human Serum Albumin antibody |
|
MBS531801-5x1mg |
MyBiosource |
5x1mg |
EUR 1115 |
Human Serum Albumin Antibody |
|
MBS568369-1mg |
MyBiosource |
1mg |
EUR 850 |
Human Serum Albumin Antibody |
|
MBS568369-5x1mg |
MyBiosource |
5x1mg |
EUR 3620 |
Human Serum Albumin antibody |
|
MBS530045-1mg |
MyBiosource |
1mg |
EUR 590 |
Human Serum Albumin antibody |
|
MBS530045-5x1mg |
MyBiosource |
5x1mg |
EUR 2510 |
Human Serum Albumin antibody |
|
MBS530210-1mg |
MyBiosource |
1mg |
EUR 560 |
Human Serum Albumin antibody |
|
MBS530210-5x1mg |
MyBiosource |
5x1mg |
EUR 2365 |
Human Serum Albumin antibody |
|
MBS531220-1mg |
MyBiosource |
1mg |
EUR 305 |
Human Serum Albumin antibody |
|
MBS531220-5x1mg |
MyBiosource |
5x1mg |
EUR 1230 |
Human Serum Albumin antibody |
|
MBS531328-1mg |
MyBiosource |
1mg |
EUR 575 |
Human Serum Albumin antibody |
|
MBS531328-5x1mg |
MyBiosource |
5x1mg |
EUR 2430 |
Human Serum Albumin antibody |
|
MBS534372-1mg |
MyBiosource |
1mg |
EUR 3120 |
Human Serum Albumin antibody |
|
MBS534372-5x1mg |
MyBiosource |
5x1mg |
EUR 13890 |
Human Serum Albumin antibody |
|
MBS535895-1mg |
MyBiosource |
1mg |
EUR 400 |
Human Serum Albumin antibody |
|
MBS535895-5x1mg |
MyBiosource |
5x1mg |
EUR 1660 |
Human Serum Albumin antibody |
|
MBS530733-1mg |
MyBiosource |
1mg |
EUR 590 |
Human Serum Albumin antibody |
|
MBS530733-5x1mg |
MyBiosource |
5x1mg |
EUR 2510 |
Human Serum Albumin Antibody |
|
MBS8584798-01mL |
MyBiosource |
0.1mL |
EUR 305 |
Human Serum Albumin Antibody |
|
MBS8584798-01mLAF405L |
MyBiosource |
0.1mL(AF405L) |
EUR 565 |
Human Serum Albumin Antibody |
|
MBS8584798-01mLAF405S |
MyBiosource |
0.1mL(AF405S) |
EUR 565 |
Human Serum Albumin Antibody |
|
MBS8584798-01mLAF610 |
MyBiosource |
0.1mL(AF610) |
EUR 565 |
Human Serum Albumin Antibody |
|
MBS8584798-01mLAF635 |
MyBiosource |
0.1mL(AF635) |
EUR 565 |
Human Serum Albumin Antibody |
|
MBS9215542-01mL |
MyBiosource |
0.1mL |
EUR 425 |
Human Serum Albumin Antibody |
|
MBS9215542-5x01mL |
MyBiosource |
5x0.1mL |
EUR 1887 |
Human Serum Albumin Antibody |
|
MBS9215568-01mL |
MyBiosource |
0.1mL |
EUR 425 |
Human Serum Albumin Antibody |
|
MBS9215568-5x01mL |
MyBiosource |
5x0.1mL |
EUR 1887 |
Human Serum Albumin Antibody |
|
MBS8565969-01mL |
MyBiosource |
0.1mL |
EUR 310 |
Human Serum Albumin Antibody |
|
MBS9434935-005mL |
MyBiosource |
0.05mL |
EUR 325 |
Human Serum Albumin Antibody |
|
MBS9434935-01mL |
MyBiosource |
0.1mL |
EUR 445 |
Human Serum Albumin Antibody |
|
MBS9434935-5x01mL |
MyBiosource |
5x0.1mL |
EUR 1860 |
 Mouse Anti Human Serum Albumin Monoclonal Antibody |
|
DMABT-49278MH |
Creative Diagnostics |
0.2 mg |
EUR 525 |
|
|
|
Description: Mouse |
 Bovine Serum Albumin Antibody |
|
20-abx133923 |
Abbexa |
-
Ask for price
-
Ask for price
-
Ask for price
|
|
|
|
Bovine Serum Albumin Antibody |
|
20-abx133926 |
Abbexa |
-
Ask for price
-
Ask for price
-
Ask for price
|
|
|
|
) Serum Albumin Antibody (Biotin) |
|
20-abx134561 |
Abbexa |
-
Ask for price
-
Ask for price
-
Ask for price
|
|
|
|
Bovine Serum Albumin Antibody |
|
20-abx134562 |
Abbexa |
-
Ask for price
-
Ask for price
-
Ask for price
|
|
|
|
Following discussions with ICMR program officers, the NCU formulated normal working procedures for moral conduct, knowledge assortment, knowledge sharing, progress reporting procedures, and manuscript preparation for all analysis initiatives. Regularly scheduled long-distance communications with investigators utilizing social media and group communications have been deliberate. NCU partnered with the ICMR Database Management Unit to construct a shared on-line platform for real-time knowledge entry and storage, and organized two undertaking evaluation conferences the place it additionally coordinated with US college to prepare public workshops on manuscript writing and qualitative analysis.
